Targeted Bias: The Next Swing at IL2 Therapy

Despite its long history of toxicity and limited efficacy, IL2 has re-entered the clinic as a companion to the recently FDA-approved tumor infiltrating lymphocyte therapy. In back-to-back articles, Moynihan and Kaptein introduce a new fusion protein that delivers a biased IL2 mutein to CD8 T cells.

See related article by Moynihan et al., p. 1206 (6).

See related article by Kaptein et al., p. 1226 (7).